Clinical predictors for survival with the addition of chemotherapy in patients with recurrent-metastatic squamous cell carcinoma of the head and neck after progression on immune checkpoint inhibitors

被引：1
|
作者：
Issa, M. [1 ]
Klamer, B. [2 ]
Bhateja, P. [3 ]
Karivedu, V. [3 ]
Laliotis, G. [4 ]
Dibs, K. [5 ]
Mladkova, N. [5 ]
Pan, X.
Old, M. [5 ]
Gamez, M. [5 ]
Grecula, J. [5 ]
Jhawar, S. [5 ]
Mitchell, D. [5 ]
Baliga, S. [5 ]
Carrau, R. [6 ]
Rocco, J. [6 ]
Bonomi, M. [3 ]
Blakaj, D.
机构：
[1] Ohio State Univ, Med Oncol, James Canc Hosp, Columbus, OH USA
[2] Ohio State Univ, Sch Biomed Sci, Ctr Biostat, OSUCCC,Comprehens Canc Ctr, Columbus, OH USA
[3] Ohio State Univ, Dept Med Oncol, OSUCCC, Comprehens Canc Ctr, Columbus, OH USA
[4] Sidney Kimmel Comprehensive Canc Ctr, Med Oncol, Baltimore, MD USA
[5] Ohio State Univ, Radiat Oncol, Comprehens Canc Ctr, OSUCCC, Columbus, OH USA
[6] Ohio State Univ, Otolaryngol, James Canc Hosp, Columbus, OH USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1298
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
888P
引用
收藏
页码：S797 / S798
页数：2
相关论文
共 50 条
  • [21] Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study
    Wakasaki, Takahiro
    Manako, Tomomi
    Yasumatsu, Ryuji
    Hara, Hirotaka
    Toh, Satoshi
    Masuda, Muneyuki
    Yamauchi, Moriyasu
    Kuratomi, Yuichiro
    Nishimura, Emi
    Takeuchi, Toranoshin
    Matsuo, Mioko
    Jiromaru, Rina
    Hashimoto, Kazuki
    Komune, Noritaka
    Nakagawa, Takashi
    PLOS ONE, 2022, 17 (07):
  • [22] Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma
    Ducoulombier, Agnes
    Guigay, Joel
    Etienne-Grimaldi, Marie-Christine
    Saada-Bouzid, Esma
    CURRENT OPINION IN ONCOLOGY, 2023, 35 (03) : 166 - 177
  • [23] Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival
    Lien, Ming-Yu
    Wang, Ti-Hao
    Hsieh, Ching-Yun
    Tsai, Ming-Hsui
    Hua, Chun-Hung
    Cheng, Fu-Ming
    Chung, Wen-Hui
    Tang, Chih-Hsin
    Hsieh, Jason Chia-Hsun
    ORAL ONCOLOGY, 2021, 119
  • [24] Response to salvage chemotherapy with paclitaxel plus /cetuximab after progression on immune checkpoint inhibitors in platinum-refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (CeTax study)
    Gomez, R. G. Herrera
    Saleh, K.
    Auclin, E.
    Vinches, M.
    Gervais, C.
    Espeli, V. G.
    Rothschild, S. I.
    Even, C.
    Cristina, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S592 - S592
  • [25] Immune Checkpoint Inhibitors for Head and Neck Squamous Cell Carcinoma-Reply
    Mastrolonardo, Eric V.
    Llerena, Pablo
    Curry, Joseph M.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2025, 151 (02)
  • [26] Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
    Vellanki, Paz J.
    Marur, Shanthi
    Bandaru, Pradeep
    Mishra-Kalyani, Pallavi Shruti
    By, Kunthel
    Girvin, Andrew
    Chatterjee, Somak
    Singh, Harpreet
    Keegan, Patricia
    Larkins, Erin A.
    Cross, Frank
    Pazdur, Richard
    Theoret, Marc R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma"
    Haridevamuthu, B.
    ORAL ONCOLOGY, 2024, 156
  • [28] Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis
    Dang, Shoutao
    Li, Xinyu
    Liu, Heshu
    Zhang, Shuyang
    Li, Wei
    CANCER MEDICINE, 2024, 13 (07):
  • [29] Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma
    Iwaki, Sho
    Kadowaki, Shigenori
    Honda, Kazunori
    Narita, Yukiya
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Ando, Masashi
    Muro, Kei
    Sawabe, Michi
    Suzuki, Hidenori
    Nishikawa, Daisuke
    Beppu, Shintaro
    Terada, Hoshino
    Kishikawa, Toshihiro
    Kawakita, Daisuke
    Hanai, Nobuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (06) : 764 - 770
  • [30] Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck
    Machiels, Jean-Pascal
    Schmitz, Sandra
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (03) : 359 - 371
12345